JPRN-UMIN000032585已完成2 期
Phase II study of atezolizumab for advanced non-small-cell lung cancer patients not indicative of cytotoxic chemotherapy - atezolizuamab for NSCLC with poor PS
Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital0 个研究点目标入组 64 人开始时间: 2018年7月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) The age of less than 20 2) Indicative for cytotoxic chemotherapy or molecular targeted agents 3) Uncontrolled brain metastasis treated by palliative radiotherapy 4) Clinically active infection 5) Severe complication (cardiac diseases, interstitial pneumonia, uncontrolled hypertension or diabetes) 6) Uncontrolled pleural effusion 7) Active other organ cancers 8) History of severe drug allergy 9) Uncontrolled digestive ulcer 10) Any patients judged by the investigator to be unfit to participate in the study
研究者
相似试验
进行中（未招募）
1 期
Study to assess efficacy of Atezolizumab in combination with Carboplatin Plus Pemetrexed in patients who are chemotherapy-naïve and have stage IV non-squamous non-small cell lung cancer with asymptomatic brain metastases (ATEZO-BRAIN)Atezolizumab combined with carboplatin and pemetrexedMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2017-005154-11-ESSpanish Lung Cancer Group (SLCG/GECP)40
招募中
2 期
PhaseII study of Atezolizumab plus Chemotherapy in PS 2 Patients With Non-Sq NSCLCJPRN-jRCTs041210030Murakami Haruyasu20
进行中（未招募）
2 期
CCH1907/MK008 trialunresectable alveolar soft tissue sarcomaadvanced alveolar soft part sarcomaD018234JPRN-jRCT2031200041Yonemori Kan20
进行中（未招募）
1 期
Atezolizumab in Advanced Non-small cell lung cancer with rare histologiesEUCTR2018-002607-34-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)43
招募中
2 期
OGIK2301(RELIANCE)on-small cell lung cancerNon-small cell lung cancerJPRN-jRCTs071230065Yamaguchi Masafumi33